hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06291870 id: F4396-P id: IRB-22-01-4294 type: OTHER domain: John D. Dingell VA Medical Center briefTitle: Predictors of Post-COVID Clinical and Cognitive Consequences acronym: SCLC overallStatus: RECRUITING date: 2023-01-19 date: 2025-07-30 date: 2025-12-30 date: 2024-03-04 date: 2024-04-01 name: VA Office of Research and Development class: FED name: John D. Dingell VA Medical Center briefSummary: The CDC describes Post-acute sequelae of SARS-COV-2 infection (PASC) for the wide range of physical and mental health consequences experienced by some patients. These sequelae may be present four or more weeks after SARS-COV-2 infection, including patients who had initial mild or asymptomatic acute infection. However, there is complete absence of data whether chronic sleep changes due to COVID-19 infection may influence these physical and mental health consequences. While fatigue is one of the common post-COVID conditions, there are no systematic examinations of sleep disturbances in COVID-19 survivors. This will be a pilot observational retrospective and prospective cohort study, to systematically assess if sleep disturbances and severity of sleep apnea comprise a modifiable facet of PASC as well as the short-term and longer-term effects of COVID-19 infection itself on sleep, cognitive function, exercise capacity and lung function. conditions: Post Acute Sequelae of SARS CoV 2 Infection conditions: Obstructive Sleep Apnea studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 120 type: ESTIMATED measure: Neurocognitive function Trails A and Trails B measure: Neurocognitive function PASAT measure: Neurocognitive function Stroop color-word interference measure: Neurocognitive function DIGIT measure: Neurocognitive function WASI measure: Neurocognitive function WMS measure: Neurocognitive function PVT measure: Neurocognitive function HVLT-R measure: Sleepiness ESS measure: Sleep quality PSQI measure: Quality of life SF-36v2 measure: Quality of life FOSQ measure: Quality of life SGRQ measure: Fatigue Severity measure: PROMISE Sleep Disturbance measure: Horne and Osteberg Morningness/Eveningness Questionnaire measure: Mini Mental State Examination (MMSE) measure: Borg Scale measure: Dyspnea: Six-minute walk test (6MWT) distance sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: John D. Dingell VA Medical Center, Detroit, MI status: RECRUITING city: Detroit state: Michigan zip: 48201-1916 country: United States name: Ruchi Rastogi, MS role: CONTACT phone: 313-576-4464 email: ruchi.rastogi@va.gov name: Susmita Chowdhuri, MD, MS role: PRINCIPAL_INVESTIGATOR lat: 42.33143 lon: -83.04575 hasResults: False
nctId: NCT06291844 id: Cohort-Mata-2023-1 briefTitle: Ocular Trauma and COVID-19 in Indonesia overallStatus: COMPLETED date: 2021-01-01 date: 2022-03-31 date: 2023-06-01 date: 2024-03-04 date: 2024-03-04 name: Prof. R. D. Kandou General Hospital class: OTHER briefSummary: Ocular injuries, a significant contributor to avoidable blindness globally, impact approximately 55 million individuals each year. Prompt initial treatment is vital for improving vision, yet the scarcity of skilled eye specialists often results in overcrowding at advanced medical centers. Moreover, the COVID-19 outbreak has introduced distinct factors into the management of ocular trauma. This research investigated the epidemiology of ocular injuries during the pandemic and offered observations on the distinctive hurdles and trends encountered. conditions: Ophthalmological Disorder conditions: Ocular Injury conditions: COVID-19 studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 13 type: ACTUAL measure: Ocular Trauma sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Ophthalmology, Prof. R. D. Kandou General Hospital - Faculty of Medicine, Sam Ratulangi University city: Manado state: North Sulawesi country: Indonesia lat: 1.48218 lon: 124.84892 hasResults: False
nctId: NCT06291831 id: C4671050 briefTitle: A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain. overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-13 date: 2024-05-13 date: 2024-05-13 date: 2024-03-04 date: 2024-04-09 name: Pfizer class: INDUSTRY briefSummary: The purpose of this study is to collect information on the:
* are 18 years of age or older. This study will help to inform decision-making on use of Paxlovid at the national level. conditions: COVID-19 studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 3000 type: ESTIMATED name: nirmatrelvir, ritonavir name: Controls measure: Demographic characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Age measure: Demographic characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Gender measure: Demographic characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Ethnicity measure: Demographic characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Education measure: Demographic characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Employment status measure: Clinical characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Height measure: Clinical characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Weight measure: Clinical characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Body Mass Index (BMI) measure: Clinical characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Smoking status measure: Clinical characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Pre-existing Comorbidities measure: Clinical characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Concomitant medications for comorbidities at index date measure: Clinical characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Medications used to treat COVID-19 measure: Assessment of all Participants HRU: Inpatient setting measure: Assessment of all Participants HRU sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Pfizer Gulf FZ city: Busaiteen country: Bahrain hasResults: False
nctId: NCT06291818 id: 2023-0917 briefTitle: Self-Adhering Magnetic Device to Treat Corneal Exposure overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-12-01 date: 2025-04-01 date: 2024-03-04 date: 2024-03-04 name: University of Illinois at Chicago class: OTHER briefSummary: Paralytic lagophthalmos can be difficult to treat and manage. It has a host of causes and effects, one of which (for the latter) is exposure keratopathy. Untreated, this can lead to corneal ulceration, inflammation, and potentially blindness. Despite a variety of attempts at treating this complex condition, none have satisfactorily reduced complications ranging from ease of use to aesthetics. With improvement in magnetic technology, however, that may change. Barmettler et al (2014) have demonstrated preliminary success of externally affixed magnets in closing both model and patient eyelids. As such, we hypothesize that magnetic devices can be used to treat corneal exposure by controlling eyelid position. conditions: Paralytic Lagophthalmos conditions: Corneal Exposure studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: temporary magnetic system for tarsorrhaphy (MST) primaryPurpose: OTHER masking: NONE count: 25 type: ESTIMATED name: temporary magnetic system for tarsorrhaphy (MST) measure: Number of participants with success of a temporary magnetic system for tarsorrhaphy sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Illinois - Specialty Care Building city: Chicago state: Illinois zip: 60612 country: United States name: Pete Setabutr, MD role: CONTACT phone: 312-996-9120 email: psetabut@uic.edu lat: 41.85003 lon: -87.65005 hasResults: False
nctId: NCT06291805 id: 1-10-72-189-23 briefTitle: Phenotyping and Characterization of wtATTR-CM (TRACE 1) overallStatus: RECRUITING date: 2024-02-20 date: 2025-12 date: 2025-12 date: 2024-03-04 date: 2024-03-04 name: Steen Hvitfeldt Poulsen class: OTHER name: Novo Nordisk A/S briefSummary: Descriptive cross-sectional study on 100 consecutive ATTRwt-CM patients reflecting all NAC stages aiming primarily to investigate ATTRwt-CM patient's quality of life (QoL) measures and their relation to ATTRwt-CM severity. Secondarily aiming to investigate the possibility to measure misTTR and fragTTR in plasma and urine and to detect fragTTR in endomyocardial biopsies from ATTRwt-CM patients. To investigate whether misTTR and fragTTR levels are correlated with ATTRwt-CM severity. conditions: Transthyretin Amyloidosis conditions: Transthyretin Amyloid Cardiomyopathy conditions: Wild-Type Transthyretin-Related (ATTR)Amyloidosis conditions: Quality of Life studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 120 type: ESTIMATED measure: Investigation of cardiac amyloidosis severity in patients with Wild-type Transthyretin Amyloidosis Cardiomyopathy. measure: Investigation of the relations between cardiac amyloid severity and patient quality of life in patients with Wild-type Transthyretin Amyloidosis Cardiomyopathy. measure: Assessment of transthyretin and pathogenic fragments and relation to cardiac amyloid severity in patients with Wild-type Transthyretin Amyloidosis Cardiomyopathy measure: Validation of a new amyloid specific questionnaire (ATTR-QoL) in comparison with Kansas City Cardiomyopathy Questionnaire (KCCQ) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Aarhus University Hospital status: RECRUITING city: Aarhus state: Arrhus N zip: 8200 country: Denmark name: Sie Kronborg Fensman role: CONTACT phone: +45 30 48 88 85 email: siefensman@gmail.com lat: 56.15674 lon: 10.21076 hasResults: False
nctId: NCT06291792 id: FTR001 briefTitle: Otago Exercise Program Applied By Telerehabilitation acronym: OEPABT overallStatus: RECRUITING date: 2023-11-01 date: 2024-03-01 date: 2024-03-01 date: 2024-03-04 date: 2024-03-04 name: Sinop University class: OTHER briefSummary: The aim of this study is to examine the effects of Otago Exercise Program (OEP) on pain, walking speed, lower extremity muscle strength, fear of falling, anxiety, quality of life and balance with the telerehabilitation method in individuals with a history of falling, which is frequently seen in elderly individuals due to aging.
45 people between the ages of 65 and 78 participated in the study. They were randomly divided into 3 groups as control, telerehabilitation otago exercise program (TOEG) and face-to-face otago exercise program (FOEG). 45 minutes of OEP was applied 3 times a week for 8 weeks. Pain, walking speed, lower extremity muscle strength, fear of falling, anxiety, quality of life, and balance were evaluated before the Otago Exercise Program, at the 4th week, at the 8th week, and 4 weeks after the end of the exercise program. Significance was evaluated at the p\<0.05 level in the study. conditions: Older People--Abuse of conditions: Falling conditions: Balance; Distorted studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 40 type: ESTIMATED name: telerehabilitation otago exercise program name: face to face otago exercise program measure: Numerical Pain Scale measure: Walking Speed measure: lower extremity muscle strength measure: Fall effectiveness scale measure: Beck anxiety scale measure: Tinetti balance and walking test measure: World Health Organization Quality of Life Scale: sex: ALL minimumAge: 65 Years maximumAge: 90 Years stdAges: OLDER_ADULT facility: Bahçeşehir University research application center status: RECRUITING city: Istanbul country: Turkey name: Sefa Haktan Hatık, PhD role: CONTACT email: haktanhtk@gmail.com lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06291779 id: SNUBH-GS- HBP5 id: E-2211-792-350 (local IRB) type: OTHER domain: Seoul National University Bundang Hospital briefTitle: Diagnosis of Pancreatic Cancer by Purine Metabolite (Hypoxanthine, Xanthine) in Urine overallStatus: RECRUITING date: 2022-11-30 date: 2024-02-26 date: 2024-05-31 date: 2024-03-04 date: 2024-03-04 name: Ho-Seong Han class: OTHER name: Seoul National University Bundang Hospital briefSummary: * This study aim to develope a diagnostic method of pancreatic cancer by using a reagent for analyzing purine metabolite (Hypoxanthine, Xanthine) in urine.
* It is safe and cost effective compare to radiologic or blood test. It can be used for initial screening test for healty population. conditions: Pancreas Cancer conditions: Diagnosis studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 120 type: ESTIMATED name: Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio measure: Urine sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ho-Seong Han status: RECRUITING city: Seongnam state: Gyeonggi-do country: Korea, Republic of lat: 37.43861 lon: 127.13778 hasResults: False
nctId: NCT06291766 id: 2022-05498-01 briefTitle: Gestational Diabetes After Gastric Bypass Surgery overallStatus: RECRUITING date: 2024-01-01 date: 2028-12 date: 2035-12 date: 2024-03-04 date: 2024-03-04 name: Region Skane class: OTHER briefSummary: The goal of this trial is to compare different means of glucose monitoring in women with gestational diabetes and a history of gastric bypass surgery.
Participants will be randomized to either continous glucose monitoring or regular capillary glucose measurements during the last trimester of their pregnancy. Researchers will compare the glucose measurement outcomes, the glucose lowering treatment given and pregnancy outcomes between groups. conditions: Diabetes, Gestational conditions: Gastric Bypass Status for Obesity Complicating Pregnancy, Childbirth, or the Puerperium conditions: Pregnancy in Diabetic conditions: Blood Glucose Self Monitoring studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 120 type: ESTIMATED name: FreeStyle Libre 2, continous glucose monitoring measure: Adverse Pregnancy Outcome measure: Glucose values measure: Glucose values measure: Glucose values measure: Glucose values measure: Glucose values measure: Pharmacological treatment measure: Pharmacological treatment measure: Pharmacological treatment measure: Pharmacological treatment measure: Birthweight measure: Week of delivery sex: FEMALE minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Region Skane status: RECRUITING city: Lund zip: 221 85 country: Sweden name: Ulrika Moll, MD, PhD role: CONTACT lat: 55.70584 lon: 13.19321 hasResults: False
nctId: NCT06291753 id: SL-B2023-478-01 briefTitle: Characteristics and Tumor Staging Proposal for Primary Malignant Melanoma of the Esophagus overallStatus: COMPLETED date: 2023-09-22 date: 2024-02-18 date: 2024-02-18 date: 2024-03-04 date: 2024-03-04 name: Sun Yat-sen University class: OTHER briefSummary: Background: Primary malignant melanoma of the esophagus (PMME) is a malignant tumor originating from esophageal melanocytes with a poor prognosis. No international clinical guidelines or tumor staging systems have been proposed for PMME. This study aimed to analyze the clinical characteristics and treatment outcomes of patients with PMME and propose a tumor staging system in PMME.
Materials and Methods: The clinical characteristics of 25 patients with PMME at our cancer center were summarized, and 21 patients were enrolled in a pooled analysis with 162 cases (extracted from 74 eligible articles in PubMed) for further survival analysis and proposal of PMME tumor staging. conditions: Primary Malignant Melanoma of the Esophagus studyType: OBSERVATIONAL observationalModel: CASE_CROSSOVER timePerspective: RETROSPECTIVE count: 25 type: ACTUAL measure: Overall Survival(OS) measure: Disease-free survival (DFS) sex: ALL minimumAge: 23 Years maximumAge: 72 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Qianwen Liu city: Guangzhou state: Guangdong country: China lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06291740 id: MTU-EC-EM-2-008/67 id: Faculty of Medicine type: OTHER domain: Thammasat University, Thailand briefTitle: Continuous Versus Intermittent Nebulization Therapy in Acute Asthma Exacerbation at Emergency Department overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-04 date: 2025-05 date: 2024-03-04 date: 2024-03-04 name: Thammasat University class: OTHER briefSummary: The goal of this clinical is to compare treatment outcomes between continuous nebulization and intermittent therapy in the management of acute exacerbation of asthma in the emergency department(ED). Participants will random assign to either continuous or intermittent nebulization. In the continuous group, patients receive budesonide, fenoterol, ipratropium bromide, and normal saline continuously for an hour. In the intermittent group, the same medications are administer every 20 minutes for an hour. Measurements include symptom severity, respiratory rate, oxygen saturation, and pulmonary function tests. Primary endpoints are ED stay length, hospital admission, and ED revisit within 48 hours post-discharge. Adverse events are documented. conditions: Asthma Exacerbation conditions: Emergency Department conditions: Nebulization studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: randomized controlled trial (RCT) primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: continuous nebulization name: Intermittent nebulization measure: Length of ED stay measure: pulmonary function test measure: Hospital admission measure: ED revisit within 48 hours sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06291727 id: Prisma Upstate briefTitle: Mepivacaine vs Bupivacaine Spinal Anesthesia for TKA overallStatus: RECRUITING date: 2024-02-16 date: 2025-07-01 date: 2025-07-01 date: 2024-03-04 date: 2024-03-04 name: Prisma Health-Upstate class: OTHER briefSummary: This study is a prospective, double-blind prospective randomized controlled trial comparing mepivacaine and bupivacaine spinal anesthesia for same-day discharge readiness following a unilateral primary elective TKA procedure.
Study data will be collected during the patient's hospital stay for their TKA procedure, and the primary outcome of same-day discharge readiness will be assessed the day of surgery. Patients will also be contacted at Day 3 post-op to assess for any complications, current level of pain, and pain medication utilization. conditions: Anesthesia, Spinal conditions: Arthroplasty, Replacement, Knee studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Patients will be randomized 1:1 to one of two groups; one receiving Mepivacaine spinal anesthesia and the other receiving Bupivacaine spinal anesthesia for total knee arthroplasty (TKA). primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Investigators and participants will not know which anesthetic agent they receive. Anesthesia providers will be aware in order to provide correct randomization. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 138 type: ESTIMATED name: Mepivacaine name: Bupivacaine measure: Same day discharge rate measure: Post-operative pain score as assessed by numeric rating scale (NRS) measure: Urinary retention as assessed by time at which patient can voluntarily void bladder post-operatively measure: Return of sensory and motor function as assessed by ability of patient to plantar and dorsiflex lower extremity measure: Post-operative nausea and vomiting as assessed by clinical documentation of nausea and vomiting post-operatively measure: Pain Medications as evaluated by medical morphine equivalents measure: Patient satisfaction levels as assessed by a 5-item Likert response scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Prisma Health Patewood Hospital status: RECRUITING city: Greenville state: South Carolina zip: 29615 country: United States name: Kyle Adams role: CONTACT phone: 864-455-3449 email: Kyle.Adams@prismahealth.org lat: 34.85262 lon: -82.39401 hasResults: False
nctId: NCT06291714 id: Clearsight briefTitle: Non-invasive Measurement of the Hypotension Prediction Index for the Reduction of Intraoperative Hypotension acronym: Clearsight overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-03-31 date: 2026-03-31 date: 2024-03-04 date: 2024-03-15 name: University of Giessen class: OTHER name: Edwards Lifesciences briefSummary: In order to reduce the incidence of IOH, various goal-directed therapy (GDT) protocols have already been introduced with success regarding the reduction of postoperative AKI and MINS. However, these studies used an invasive hemodynamic monitoring which offered a continuous surveillance of the blood pressure. In contrast, standard non-invasive blood pressure monitoring results in a blind gap between two measurements (mostly three or five minutes). In order to address this limitation, different continuous non-invasive blood pressure monitoring devices have been introduced. The next evolutional step of non-invasive cardiac output monitoring was to prevent IOH before their onset by using the Hypotension Prediction Index (HPI). Based on the Edward ́s monitoring platform, HPI is a monitoring tool which aims to predict IOH (defined as MAP\<65 mmHg for at least one minute) up to 15 min before its onset. The underlying machine learning based algorithm uses analyses features from the pressure waveform and was first calculated from a large retrospective data set of surgical patients and subsequently validated in a prospective cohort. In this study HPI showed a sensitivity of 88% and specificity of 87% for predicting IOH 15 min before its onset. Since then, own and studies of other working groups confirmed the effective prevention of IOH by the use of HPI-based GDT. Until today the arterial waveform analysis was dependent on invasive arterial measurement but since Edwards Lifesciences already promoted the start of the HPI on the ClearSight platform a non-invasive measurement will soon be possible.